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Abstract
Background: Anticancer bisdioxopiperazines, including ICRF-154, razoxane (Raz, ICRF-159) and ICRF-193, are a family of
anticancer agents developed in the UK, especially targeting metastases of neoplasms. Two other bisdioxopiperazine derivatives,
probimane (Pro) and MST-16, were synthesized at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences,
Shanghai, China. Cytotoxic activities and mechanisms of Raz (+)-steroisomer (ICRF-187, dexrazoxane), Pro and MST-16 against
tumor cells were evaluated by MTT colorimetry, flow cytometry and karyotyping.
Results: Pro was cytotoxic to human tumor cell lines in vitro (IC50<50 µM for 48 h). Four human tumor cell lines (SCG-7901,
K562, A549 and HL60) were susceptible to Pro at low inhibitory concentrations (IC50 values < 10 µM for 48 h). Although the
IC50 against HeLa cell line of vincristine (VCR, 4.56 µM), doxorubicin (Dox, 1.12 µM) and 5-fluoruouracil (5-Fu, 0.232 µM) are
lower than Pro (5.12 µM), ICRF-187 (129 µM) and MST-16 (26.4 µM), VCR, Dox and 5-Fu shows a low dose-related – high
cytotoxic activity. Time-response studies showed that the cytotoxic effects of Pro are increased for 3 days in human tumor cells,
whereas VCR, Dox and 5-Fu showed decreased cytotoxic action after 24 h. Cell cycle G2/M phase arrest and chromosome
segregation blocking by Pro and MST-16 were noted. Although there was similar effects of Pro and MST-16 on chromosome
segregation blocking action and cell cycle G2/M phase arrest at 1- 4 µM, cytotoxicity of Pro against tumor cells was higher than
that of MST-16 in vitro by a factor of 3- 10 folds. Our data show that Pro may be more effective against lung cancer and leukemia
while ICRF-187 and MST-16 shows similar IC50 values only against leukemia.
Conclusion:  It suggests that Pro has a wider spectrum of cytotoxic effects against human tumor cells than other
bisdioxopiperazines, especially against solid tumors, and with a single cytotoxic pathway of Pro and MST-16 affecting
chromosome segregation and leading also to cell G2/ M phase arrests, which finally reduces cell division rates. Pro may be more
potent than MST-16 in cytotoxicity. High dose- and time- responses of Pro, when compared with VCR, 5-Fu and Dox, were
seen that suggest a selectivity of Pro against tumor growth. Compounds of bisdioxopiperazines family may keep up their
cytotoxic effects longer than many other anticancer drugs.
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Background
Bisdioxopiperazines, including ICRF-154, razoxane
(ICRF-159, Raz); ICRF-186 and ICRF-187), two stereo-iso-
mers of Raz, and ICRF-193, developed in the UK, were
some of the earliest agents found against a murine spon-
taneous metastatic model (Lewis lung carcinoma) in 1969
[1]. Many papers and projects have dealt with their poten-
tial use and mechanisms since that time. Three main
mechanisms of bisdioxopiperazine action have been
investigated, including assisting in radiotherapy, [2,3]
overcoming multi-drug resistance (MDR) of daunoru-
bicin and doxorubicin to leukemias [4,5] and inhibiting
topoisomerase II [6,7]. More importantly, Raz has been
licensed for cardioprotectant of anticancer anthrocyclines
in more countries. Since bisdioxopiperazines represents a
unique family of antimetastatic agents that are structurally
conservative in their pharmacological actions, two new
derivatives, probimane [1,2-bis (N4-morpholine-3, 5-
dioxopeprazine-1-yl) propane; AT-2153, Pro] and MST-
16, 1, 2- bis (4- isobutoxycarbonyloxymethyl- 3, 5- dioxo-
piperazin-1- yl) ethane were synthesized at this institute
in Shanghai, China. [8,9]. Apart from data of anti-tumor
activity [10-12], the pharmacological mechanisms of Pro
as Raz, like the detoxication of Adriamycin (ADR), induced
cardiotoxicities and synergism with ADR against leuke-
mias were reported at Henan Academy of Medicine,
Henan, China [13]. As the main researchers of Pro, we
reported some novel biological actions of Pro, including
the inhibition of the activity of calmodulin (CaM), a cell-
signal regulator, which can explain anticancer actions and
the combined cytotoxic effect of Pro with ADR [13,14]
inhibiting lipoperoxidation (LPO) of erythrocytes [15],
down-regulating sialic acid synthesis in tumors [16] and
blocking the binding of fibrinogen to leukemia cells [17].
MST-16, as a licensed drug in Japan since 1994, was per-
mitted for direct use in leukemia chemotherapy, mainly
Structural formulae of three bisdioxopiperazines Figure 1
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against adult T-cell leukemia treatment [18]. Structural
formulae of the three bisdioxopiperazines are represented
in Figure 1.
As a new bisdioxopiperazine, the pharmacological charac-
ters and features of Pro are intriguing. Increased under-
standing of the advantages and disadvantages of the two
compounds is a first step for promoting applications of
Pro and MST-16. Therefore, in depth pharmacological
evaluation was carried out. Tumors studied are from 7 dif-
ferent organs of origin – two gastric tumor cell line (SCG-
7901, MKN-28), a lung tumor cell line (A549), a colon
cancer cell line (HCT-116), two mammary tumor cell
lines (MDA-MB-435, MDA-MB-468), one hepatic tumor
cell line (BEL7402), two leukemia cell line (HL-60 and
K562) and an uteric cervical tumor cell line (HeLa). In
addition, time- and concentration-dependent relations to
classify the effectiveness of different therapeutic schedules
and schemes of Pro and MST-16 therapy have been
addressed.
Results
Cytotoxic effects of Pro and MST-16 against human tumor 
cell lines
Data on the anticancer effects of Pro using 10 human
tumor cell lines in vitro are showed in Figure 2 and Table
1. Pro had anticancer effects in vitro at clinical acceptable
concentrations (IC50 values < 50 µM) by MTT methods.
The IC50 values of Pro are 1.3672 ± 0.6230 µM, 24.314 ±
5.465 µM, 14.476 ± 3.085 µM, 45.325 ± 5.335, 22.169 ±
1.250, 0.02947 ± 0.02456 µM, 5.3417 ± 1.245 µM, 4.786
± 1.556, 42.457 ± 2.325 µM and 18.238 ± 1.112 µM rep-
resenting tumor cells of SCG-7901 and MKN- 28 (two
human gastric tumor cell lines), HCT-116 (a human
colon tumor cell line), MDA-MB-435 and MDA-MB-468
(two human mammary tumor cell lines), A549 (a human
lung tumor cell line) and HL60 and K562 (two human
leukemia cell lines), BEL-7402 (a human hepatic tumor
cell line) and HeLa cell (a human uteric cervical tumor cell
line) respectively (Figure 2). Among these tumor cell
lines, Pro is more effective to SCG-7901 (a gastric cancer
cell line), A549 (a lung cancer cell line) and HL60 and
K562 (two leukemia cell lines), the IC50 values being ≤ 10
µM.
Comparison of the cytotoxic effects of 
bisdioxopiperazines with other drugs
The cytotoxic effects against tumor cell lines (p388, HL-60
and HeLa cells) are included in Table 1. Although IC50s of
Dox, VCR and 5-Fu are lower than that of Pro, the greatest
inhibitory rates of Pro at high concentrations are seen
(Table 2). No inhibitory difference between low and high
concentrations of Dox, VCR and 5-Fu was observed (Table
3). Generally, the LD50 of VCR and Dox in experimental
Anticancer activities of probimane in vitro Figure 2
Anticancer activities of probimane in vitro. MTT method is 
used. Pro exposures for 48 h at 5 different concentrations. n 
= 3 and in 2 independent tests.
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Table 1: The IC50 values of Pro in different human tumor cell 
lines for 48 h. MTT method was used.
Cell origin Cell types IC50 µM; mean ± SD
Gastric SCG-7901 1.3672 ± 0.6230
MKN-28 24.314 ± 5.465
Colon HCT-116 14.476 ± 3.085
Mammary MDA-MB-435 45.325 ± 5.335
MDA-MB-468 22.169 ± 1.250
Pulmonary A549 0.02947 ± 0.02456
Leukemia HL-60 5.3417 ± 1.245
K562 4.786 ± 1.556
Uteric cervical HeLa 18.238 ± 1.112
Hepatic BEL-7402 42.457 ± 2.325
Table 2: Cytotoxic effects of anticancer drugs against tumor cell 
lines in vitro; drug exposure for 48 h
Compounds IC50 µM
P388 HL-60 HeLa
Doxorubicin 11.7 0.005 1.12
Vincristine No effect 0.05 4.56
5-fluorouracil 22.6 0.04 0.23
Probimane 64.6 1.97 5.12
ICRF-187 64.0 3.73 129
MST-16 5.23 33.4 26.4BMC Pharmacology 2005, 5:11 http://www.biomedcentral.com/1471-2210/5/11
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animals and humans are dramatically lower than Pro.
These results suggest more difficult management and
wider toxicities of these drugs in their application in the
clinics, suggesting Pro may avoid these drawbacks.
Comparison of anti-tumor effects of probimane and MST-
16 and their time- response relationships
Cytotoxic effects (IC50) of probimane and MST-16 against
tumor cells were compared (Figure 3).
In addition, the time- response curves indicate that the
anti-tumor effects of Pro increase to a climax over 3 days
of drug exposure (Figures 4, 5 and 6). The cytotoxic effects
of Pro persist or rise with time, whereas those of VCR, Dox
and 5-Fu decrease after 24 h (Table 4). IC50 of both Pro
and MST-16 reduces dramatically by 72 h from 48 h. (Fig-
ures 7 and 8). The reductions of IC50 for both agents Pro
Table 3: Dose- response relations between anti-cancer drugs for cytotoxic effect against human leukemia cell line HL-60 for 24 h; * P < 
0.01; n = 3;
Compounds Concentrations OD values Mean ± SD Percentage inhibition %
Control -- 1.229 ± 0.125 --
Probimane 10.0 0.298 ± 0.010* 75.6
2.0 0.260 ± 0.005* 78.9
0.4 1.142 ± 0.010 7.1
0.08 1.199 ± 0.012 2.4
Doxorubicin 10.0 0.256 ± 0.021* 79.2
2.0 0.266 ± 0.013* 78.3
0.4 0.312 ± 0.016* 74.5
0.08 0.408 ± 0.031* 66.9
5-Fluorouracil 5.0 0.421 ± 0.021* 65.6
1.0 0.518 ± 0.012* 57.9
0.2 0.585 ± 0.025* 54.4
0.04 0.892 ± 0.038* 27.5
Vincristine 5.0 0.425 ± 0.010* 65.4
1.0 0.423 ± 0.009* 65.6
0.2 0.401 ± 0.009* 67.4
0.04 0.394 ± 0.012* 68.0
The IC50 of probimane and MST-16 on 3 human tumor cell  lines (SCG-7901, HCT-116 and MDA-MB-468) for 48 h  exposure Figure 3
The IC50 of probimane and MST-16 on 3 human tumor cell 
lines (SCG-7901, HCT-116 and MDA-MB-468) for 48 h 
exposure. MTT method was used.
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Time – response curve of probimane inhibiting a human  mammary cell line (MDA-MB-468) Figure 4
Time – response curve of probimane inhibiting a human 
mammary cell line (MDA-MB-468). MTT method was used. 
A: Pro concentration at 5 µM (dark); B: Pro concentration at 
0.5 µM (purple).
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or MST-16 depend on the cell line. IC50 ratios of Pro and
MST-16 for 3 days relative to 2 days against the most
metastatic phenotype tumor cell line MDA-MB-435, are
8.9 and 7.5 times higher, and 2.6 times for the medium
metastatic phenotype of MDA-MB-468 cells.
G2 and M phase arrests induced by Pro or MST-16
Our data shows that both probimane (Pro) and MST-16
can arrest tumor cells in G2 and M phases of the cell cycle.
Dose- and/ or concentration- dependency are observed in
G2 and M arrests (Figures 9 to 12), and the arresting effect
of Pro on MDA-MB-435 and HCT-116 is only 2 times
higher for MST-16 at equivalent concentrations. Pro at 4
µM can increase G2/M accumulation from 16.8 % (vehicle
control) to 86.4 % after 24 h (p < 0.001, n = 3).
Chromosome segregation inhibition by Pro and MST-16
Chromosome linkages, aggregations and segregation in
tumor cells were blocked by both Pro and MST-16. Figure
13 and 14 show linkages and segregation blockade of
chromosomes in cells treated with Pro and MST-16 at 4
µM. Despite this, chromosomes began to separate with
each other, and their morphology became slimmer at
lower concentration 1µM in both human mammary
tumors of MDA-MB-436 cells and MDA-MB-468 cell lines
in vitro. This chromosome poisoning action of Pro, MST-
16 and ICRF-187 was seen at 1- 4 µM. In vehicle control
group, chromosomes of tumor cells separated from each
other very well. Although we only show typically one or
two cells, the chromosomal characteristics in each group
have an overall consistency (> 80 %) in each piece of prep-
aration from cell treated with Pro, MST-16 and ICRF-187.
They are common characteristics and phenotypes induced
by the three compounds. In addition, there seems no dif-
ference in overall chromosome effects of Pro and MST-16
at equivalent concentrations (Figures 13 and 14), suggests
that Pro and MST-16 act equally in this pathway.
Discussion
Increased understanding over the mechanisms of bisdiox-
opopiperazines can greatly improve their indications and
narrow down contraindicates in clinical practice. The
explanations for the anticancer actions of bisdioxopipera-
zine are currently focusing on anti-angiogeneses [19,20]
and tumor cell DNA alterations caused by topoisomerase
II. Generally speaking, most angiogenesis inhibitors often
have low cytotoxicity and are ineffective against larger
tumor masses, and are better combined with cytotoxic
drugs clinically [21,22]. This work on the anticancer activ-
ity of Pro and MST-16 shows that they act through the
blocking of chromosomal segregation and G2/M phase
arrests, causing complete inhibition of tumor cell divi-
sion. Pro, MST-16 and ICRF-187 play similar roles at equi-
molar concentrations. This pathway may be related to
topoismerase II inhibition [23] as a possible mode of
tumor growth inhibition, but is not suggested as a system-
atic approach through a cascade series. Two findings in
this study need further discussion; (i) the effective ranges
of Pro and MST-16 in the blocking of chromosome segre-
gation, and causing G2/M phase arrests are 1- 4 µM, simi-
lar for Pro and MST-16. This suggests the two processes
Time- response curve of probimane inhibiting a human gas- tric tumor cell line SCG-7901 Figure 5
Time- response curve of probimane inhibiting a human gas-
tric tumor cell line SCG-7901. MTT method was used. A: 
Pro concentration at 5 µM
Time- response curve of probimane inhibiting a human mam- mary cell line (MDA-MB-435) Figure 6
Time- response curve of probimane inhibiting a human mam-
mary cell line (MDA-MB-435). MTT method was used. A: Pro 
concentration at 50 µM (dark); B: Pro concentration at 5 µM 
(purple).
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operate in the same course or cascade, and most possibly
are directly linked; (ii) cyto-toxicity test (MTT) showed
that Pro was more effective than MST-16. Lacking parallels
in the effective dose ranges of Pro and MST-16 between
cyto-toxicities and chromosome segregation – induced
tumor inhibition can be explained by the fact that these
effects of Pro and MST-16 do not strictly follow the same
pathway given in Figure 15. Stronger cytotoxic effects of
Pro against many other human tumor cell lines than orig-
inal bisdioxopiperazines derivatives, especially on solid
tumors, suggest some as yet undiscovered mechanism that
Pro may have, and Pro may have better applications and
require fewer drug combinations in the future.
This work shows that anticancer activities of Pro against
lung cancer and leukemia are relatively greater than
against other tumor typies. Cytotoxic and antimetastatic
activities of Pro against lung tumor models in vivo have
also been found [24]. Lung cancer is the most prevalent
among all cancer categories, and is one of the deadliest
cancers in the clinics. Targeted at lung cancers, Pro may
offer better medical and economic benefits in the future.
For clinical chemotherapy, the paramount task is the bal-
ancing between treatment outcome and risks [25]. To
optimize chemotherapeutic protocols containing bisdiox-
opiperazines, knowledge of its pharmacological parame-
ters in terms of concentration- and time- responses are
prerequisites. We found that Pro and MST-16 might act
and accumulate longer in tumor cells than most of anti-
Table 4: The time- response relations between different anticancer drugs for cyto-toxic effects against leukemia cell line HL-60; N = 3, 
probimane, Pro; 5-fluorouracil, 5-Fu; doxorubicin, Dox; vincristine, VCR; ICRF-187, (+) stereo-isomer of razoxane
Compounds Concentrations Percentage inhibition %
µM 24 h 48 h 72 h
P r o 1 0 7 5 . 67 8 . 57 5 . 9
5 - F u 2 6 5 . 85 3 . 55 1 . 1
Dox 4 78.3 72.4 72.3
VCR 2 65.4 59.0 57.1
ICRF-187 10 47.6 37.8 42.9
MST-16 10 47.8 5.6 0.0
Differences of anticancer effects (IC50) of probimane for dif- ferent exposure intervals by a MTT method, n = 3 for 2 inde- pendent tests Figure 7
Differences of anticancer effects (IC50) of probimane for dif-
ferent exposure intervals by a MTT method, n = 3 for 2 inde-
pendent tests.
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Differences of anticancer effects (IC50) of MST-16 for differ- ent exposure intervals by a MTT method, n = 3 for 2 inde- pendent tests Figure 8
Differences of anticancer effects (IC50) of MST-16 for differ-
ent exposure intervals by a MTT method, n = 3 for 2 inde-
pendent tests.
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cancer drugs. The peak of cytotoxicity of both Pro and
MST-16 is on day 3, and not usually on day 2. This result
and our early work of auto-radiography that Pro [26]
persists longer in tumor tissues suggest that longer inter-
vals may be used between treatments and less nursing
responsibilities may arise, while maintaining high levels
of tumor growth inhibitions. The long- term cytotoxic
effects of Pro and MST-16 are more obvious in high
metastatic tumor cell lines, which can explain the selective
effects of compounds to tumor metastases. Early reports
suggest that MST-16 needs to transform into ICRF-154 to
exhibit its anticancer effects [27]. This work proves that
MST-16 does not degraded to ICRF-154, and has a lower
G2/M phase arrests of human mammary tumor cell line  (MDA-MB-435 cell) exposed to probimane at different con- centrations for 20 h Figure 9
G2/M phase arrests of human mammary tumor cell line 
(MDA-MB-435 cell) exposed to probimane at different con-
centrations for 20 h.
G2/M phase arrests of a human colon tumor cell line (HCT- 116 cell) exposed to probimane at different concentrations  for 20 h Figure 10
G2/M phase arrests of a human colon tumor cell line (HCT-
116 cell) exposed to probimane at different concentrations 
for 20 h.
G2/M phase arrests of human mammary tumor cell line  (MDA-MB-435 cell) exposed to MST-16 and probimane for  20 h Figure 11
G2/M phase arrests of human mammary tumor cell line 
(MDA-MB-435 cell) exposed to MST-16 and probimane for 
20 h. A: vehicle control; B: MST-16 0.8 µM; C: MST-16 4.0 
µM; D: Pro 2.0 µM
G2/M phase arrests of human mammary tumor cell line  (MDA-MB-435 cell) exposed to probimane for different  times Figure 12
G2/M phase arrests of human mammary tumor cell line 
(MDA-MB-435 cell) exposed to probimane for different 
times. A: vehicle control; B: Pro 6 h; C: Pro 12 h; D: Pro 24 hBMC Pharmacology 2005, 5:11 http://www.biomedcentral.com/1471-2210/5/11
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cytotoxic effects against tumor cells than Pro. Yet MST-16
can maintain a high activity in the cascade of the pro-
posed mechanism – chromosome segregation blockage
and cellular G2/M phase arrest, leading to inhibition of
cell division (Figure 15). It further suggests this mecha-
nism is not a pivotal pathway for cytotoxic activity against
tumors.
Conclusion
We suggest that Pro has a wider spectrum of cytotoxic
effects against human tumor cells than other bisdioxopi-
perazines, especially on solid tumors. The cytotoxic path-
way of Pro and MST-16 appears to be through
chromosome segregation blocking and G2/ M phase
arrests. Pro may be more potent than MST-16. High dose-
and time- related responses of Pro than VCR, 5-Fu and
Dox are seen that suggest a selectivity by Pro against
tumor growth. It suggests that the family of
bisdioxopiperazines may sustain their cytotoxic effects
longer than other anticancer drugs.
Methods
Pro and MST-16 were synthesized in this institute. Other
chemical agents were purchased from sources stated
below. The tumor cell lines were obtained from various
sources and serially passaged in this lab.
MTT method
The cells were maintained in RPMI 1640 (Gibco, Invitro-
gen Corporation, NY, USA) medium supplemented with
Chromosomal behaviors of human mammary tumor cell line- MDA-MB-435 incubated with bisdioxopiperazines Figure 13
Chromosomal behaviors of human mammary tumor cell line- MDA-MB-435 incubated with bisdioxopiperazines. A: control; B: 
probimane 4 µM; C: MST-16 4µM; D: ICRF-187 4µM.BMC Pharmacology 2005, 5:11 http://www.biomedcentral.com/1471-2210/5/11
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10 % FCS, streptomycin (100 µg/ml) and penicillin (100
units/ml). A density of 105 tumor cells /ml (90 µl) were
seeded in 96-well plates for 24 h. Pro or MST-16 (10 µl),
final concentrations indicated below, were added to each
well for incubating for the next 48 h. 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
(Sigma Company, USA) (5 mg/ ml, 20 µl) was added to
each well. Four h later, 50 µl compound solution (10 %
SDS- 5 % isobutyl alcohol-1 N HCl) were added and incu-
bated under 5 % CO2 atmospheric condition for 24 h.
Optical density at 570 nm was measured with a tunable
microplate reader, VERSAmax, USA, each group was in
triplicate samples and Pro or MST-16 were divided into 5
concentrations.
Cell cycle analysis by cytometry
Tumor cells in exponential phase were exposed to Pro or
MST-16. After 6 -24 h, cells were collected (300 × g, 10
min) and incubated with ice-cold PBS. Then fixed with
ethanol and collected and washed with PBS by
centrifugation (300 × g, 10 min). Cell deposition was
added with PBS 1 ml and RNAse (5 µl) at 37°C bath for
15 min. Cells were dyed with 5 µl PI (2 mg/ml) in dark.
Cells were measured for their DNA content by cytometry
(Becton/Dickinson – FACS Calibur) after passing through
a cell filter.
Chromosome preparation protocols
Cell chromosome preparation was by a routine proce-
dure. Human mammary tumor cells (MDA-MB-435 and
Chromosomal behaviors of human mammary tumor cell line- MDA-MB-468 incubated with bisdioxopiperazines Figure 14
Chromosomal behaviors of human mammary tumor cell line- MDA-MB-468 incubated with bisdioxopiperazines. A: control; B: 
Probimane 4 µM; C: MST-16 4µM; D: Probimane 1µM.BMC Pharmacology 2005, 5:11 http://www.biomedcentral.com/1471-2210/5/11
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MDA-MB-468) were seeded into a 6-well plate and
maintained under an atmosphere of 5 % CO2 condition.
When tumor cells covered about 60- 70 % of the surface,
bisdioxopiperazines were added. Drug – treated cells were
treated with hypotonic KCl, 0.075 M at 37°C for 30 min.
Cell nuclei were fixed with fresh-prepared fixative solu-
tion [methanol/acetic acid, 3:1] for 5 min. Cell nuclei
were collected by centrifugation (900 × g 15 min) and
washed with fixative solution by centrifugation (1500 × g
20 min). Cell nuclei were dropped onto a cooled glass
plate and placing overnight under a dehydrogenated
atmosphere. The scattered chromosomes were dyed with
a Giemsa solution for 15- 20 min and washed with tap
water. Chromosomal behaviors were viewed and photo-
graphed by microscopy with an oil-lense (LEICA, Qwin
image processing analysis system, Germany).
Statistics
IC50 of agents were calculated by software in this lab and
X ± SD was calculated from data of two groups.
List of abbreviations used are
ADR (Dox), adriamycin; VCR, vincristine; 5-Fu, 5-fluor-
ouracil; CaM, calmodulin; LPO, lipoperoxidation; Raz
(ICRF-159 or ICRF-187), razoxane; Pro, probimane; PI,
propidium iodide; MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5- diphenyl tetrazolium bromide;
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